Information Center

On February 19, 2020, the clinical trial application for "Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection" jointly submitted by Lijun Biopharmaceutical and Xinkanghe Biotech was tacitly approved by the National Medical Products Administration.

Release time:

2019-02-19 13:51

On February 19, 2020, the clinical trial application for "Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection" jointly submitted by Lijun Biopharmaceutical and Xinkanghe Biotech was tacitly approved by the National Medical Products Administration.
 


Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com

©2024 Zhejiang Kanova biopharmaceutical Co., LTD

Power by:300.cn  Beijing

Business License